Emerging evidence highlights ADORA2B as a promising therapeutic target in numerous pathological conditions, including inflammatory processes, immune responses, ischemia–reperfusion injury, fibrosis, and diabetes mellitus [45]. The gene discussed is ADORA2B; the disease is diabetes mellitus.